Skip to main content

Table 3 Characteristics of T1c patients with or without chemotherapy in the whole cohort and matched cohorts

From: Impact of adjuvant chemotherapy on T1N0M0 breast cancer patients: a propensity score matching study based on SEER database and external cohort

Characteristic

T1c: whole cohort [cases (%)]

T1c: Matched cohort [cases (%)]

Chemotherapy

P-value

Chemotherapy

P-value

No

Yes

No

Yes

GRADE

  

 < 0.01

  

0.64

 I

9648 (32.86%)

836 (7.77%)

 

777 (11.42%)

802 (11.79%)

 

 II

15,475 (52.70%)

3823 (35.55%)

 

3028 (44.52%)

2979 (43.80%)

 

 III

4239 (14.44%)

6094 (56.67%)

 

2997 (44.06%)

3021 (44.41%)

 

SURGERY

  

 < 0.01

  

0.61

 Breast-conserving

19,489 (66.37%)

6389 (59.42%)

 

3956 (58.16%)

3974 (58.42%)

 

 Total mastectomy

7640 (26.02%)

3379 (31.42%)

 

2174 (31.96%)

2190 (32.20%)

 

 Modified radical mastectomy

2233 (7.61%)

985 (9.16%)

 

672 (9.88%)

638 (9.38%)

 

RADIATION

  

0.96

  

0.41

 No

12,848 (43.76%)

4708 (43.78%)

 

3307 (48.62%)

3259 (47.91%)

 

 Yes

16,514 (56.24%)

6045 (56.22%)

 

3495 (51.38%)

3543 (52.09%)

 

SUBTYPE

  

 < 0.01

  

0.93

 HoR + /HER2-

26,924 (91.70%)

4984 (46.35%)

 

4579 (67.32%)

4579 (67.32%)

 

 HoR + /HER2 + 

973 (3.31%)

2324 (21.61%)

 

873 (12.83%)

891 (13.10%)

 

 HoR-/HER2 + 

256 ( 0.87%)

769 (7.15%)

 

246 ( 3.62%)

250 (3.68%)

 

 HoR-/HER2-

1209 (4.12%)

2676 (24.89%)

 

1104 (16.23%)

1082 (15.91%)

 

AGE (year)

  

 < 0.01

  

0.76

 < 60

10,350 (35.25%)

6891 (64.08%)

 

3645 (53.59%)

3663 (53.85%)

 

 ≥ 60

19,012 (64.75%)

3862 (35.92%)

 

3157 (46.41%)

3139 (46.15%)

 
  1. Abbreviations: HoR hormone receptor, HER‐2 human epidermal growth factor receptor‐2